ProQR Therapeutics Collaborated with Laboratoires Théa to Divest its RNA Therapies Sepofarsen and Ultevursen Ophthalmic Assets
Shots:
- ProQR will receive a $13.7M up front & will also be eligible for ~$148M in development, regulatory, and commercial fees for the rights to sepofarsen and ultevursen as well as additional earn-outs up to high teens percentage based on commercial sales in the US and EU. The transaction is expected to close in Q3’23
- With the divestment of sepofarsen and ultevursen, ProQR may continue to advance its pipeline programs AX-0810 and AX-1412 on genetic diseases originating in the liver and focus on the Axiomer RNA editing technology platform
- ProQR also develops a new class of therapies. Additionally, Sepofarsen & Ultevursen received ODD in the US & EU; FTD, and rare pediatric disease designation from the US FDA
Ref: Globenewswire | Image: ProQR
Related News:- ProQR’s Sepofarsen Failed to Meet its Primary Endpoint in P-II/III Illuminate Study for CEP290-mediated LCA10
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
